Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck

Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer

(2020) Anthony R. Cillo et al.   IMMUNITY

Development and Validation of a Combined Hypoxia and Immune Prognostic Classifier for Head and Neck Cancer

(2019) Jill M. Brooks et al.   CLINICAL CANCER RESEARCH

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

(2019) Barbara Burtness et al.   LANCET

Immunotherapy for head and neck cancer: Recent advances and future directions

(2019) John D. Cramer et al.   ORAL ONCOLOGY

Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer

(2018) Karina Kulangara et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Antitumor T-cell Reconditioning: Improving Metabolic Fitness for Optimal Cancer Immunotherapy

(2018) Dayana B. Rivadeneira et al.   CLINICAL CANCER RESEARCH

Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression

(2018) Robert L. Ferris et al.   ORAL ONCOLOGY

Abstract LB-339: Biomarkers predictive of response to pembrolizumab in head and neck cancer (HNSCC)

(2018) Tanguy Y. Seiwert et al.   CANCER RESEARCH

Metabolic Switch in the Tumor Microenvironment Determines Immune Responses to Anti-cancer Therapy

(2018) Barbara Wegiel et al.   Frontiers in Oncology

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

(2018) Ezra E W Cohen et al.   LANCET

Utility of CD8 score by automated quantitative image analysis in head and neck squamous cell carcinoma

(2018) Douglas J. Hartman et al.   ORAL ONCOLOGY

Immune suppressive mechanisms in the tumor microenvironment

(2016) David H Munn et al.   CURRENT OPINION IN IMMUNOLOGY

The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction

(2016) Nicole E. Scharping et al.   IMMUNITY

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

(2016) Tanguy Y Seiwert et al.   LANCET ONCOLOGY

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

(2016) Robert L. Ferris et al.   NEW ENGLAND JOURNAL OF MEDICINE

Current relevance of hypoxia in head and neck cancer

(2016) Marius G. Bredell et al.   Oncotarget

Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction

(2015) Ende Zhao et al.   NATURE IMMUNOLOGY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER